Fluconazole inhibits human adrenocortical steroidogenesis in vitro

Journal of Endocrinology

Volumn 215, Issue 3, 2012, Pages 403-412

  Van der Pas, R ^a   Hofland, L J ^a   Hofland, J ^a   Taylor, A E ^b   Arlt, W ^b   Steenbergen, J ^a   Van Koetsveld, P M ^a   De Herder, W W ^a   De Jong, F H ^a   Feelder, R A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYPREGNENOLONE; ANDROSTENEDIONE; CORTODOXONE; DEOXYCORTICOSTERONE; FLUCONAZOLE; HYDROXYPROGESTERONE; KETOCONAZOLE; MESSENGER RNA; PRASTERONE; PREGNENOLONE; PROGESTERONE; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE; STEROIDOGENIC ACUTE REGULATORY PROTEIN;

ADRENAL CELL; ADRENAL CORTEX; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX INSUFFICIENCY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL GROWTH; CONCENTRATION (PARAMETERS); DISEASE COURSE; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; HYPERCORTISOLISM; IN VITRO STUDY; MYCOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEROIDOGENESIS;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL CORTEX; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CORTODOXONE; DESOXYCORTICOSTERONE; FLUCONAZOLE; HUMANS; HYDROCORTISONE; KETOCONAZOLE; PREGNENOLONE; PROGESTERONE;

EID: 84872187632     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0310     Document Type: Article

References (42)

1. Albert SG, DeLeon MJ & Silverberg AB 2001 Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Critical Care Medicine 29 668-670. (doi:10.1097/00003246-200103000- 00039)
2. Anaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE, Karl C, Prince RA, Bosso J & Bodey GP 1995 Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. Journal of Infectious Diseases 172 599-602. (doi:10.1093/infdis/172.2.599)
3. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB et al. 2003 Diagnosis and complications of Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 88 5593-5602. (doi:10.1210/jc.2003- 030871)
4. Bergner R, Hoffmann M, Riedel KD, Mikus G, Henrich DM, Haefeli WE, Uppenkamp M & Walter-Sack I 2006 Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrology, Dialysis, Transplantation 21 1019-1023. (doi:10.1093/ ndt/gfi284)
5. Boscaro M, Sonino N, Rampazzo A & Mantero F 1987 Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing's disease before and after ketoconazole treatment. Clinical Endocrinology 27 461-467. (doi:10.1111/j.1365-2265.1987.tb01174.x)
6. Boscaro M, Barzon L, Fallo F & Sonino N 2001 Cushing's syndrome. Lancet 357 783-791. (doi:10.1016/S0140-6736(00)04172-6)
7. Castinetti F, Morange I, Jaquet P, Conte-Devolx B & Brue T 2008 Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. European Journal of Endocrinology 158 91-99. (doi:10.1530/EJE-07-0514)
8. ChaiW, Hofland J, Jansen PM, Garrelds IM, de Vries R, van den Bogaerdt AJ, Feelders RA, de Jong FH & Danser AH 2010 Steroidogenesis vs steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors? Journal of Hypertension 28 1044-1053. (doi:10.1097/HJH.0b013e328335c381)
9. Como JA & Dismukes WE 1994 Oral azole drugs as systemic antifungal therapy. New England Journal of Medicine 330 263-272. (doi:10.1056/ NEJM199401273300407)
10. Contreras P, Rojas A, Biagini L, Gonzalez P & Massardo T 1985 Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet 2 151-152. (doi:10.1016/S0140-6736(85)90251-X)
11. De Martin M, Pecori Giraldi F & Cavagnini F 2006 Cushing's disease. Pituitary 9 279-287. (doi:10.1007/s11102-006-0407-6)
12. Engelhardt D, Mann K, Hormann R, Braun S & Karl HJ 1983 Ketoconazole inhibits cortisol secretion of an adrenal adenoma in vivo and in vitro. Klinische Wochenschrift 61 373-375. (doi:10.1007/BF01485030)
13. Engelhardt D, Dorr G, Jaspers C & Knorr D 1985 Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klinische Wochenschrift 63 607-612. (doi:10.1007/BF01733014)
14. Farwell AP, Devlin JT & Stewart JA 1988 Total suppression of cortisol excretion by ketoconazole in the therapy of the ectopic adrenocorticotropic hormone syndrome. American Journal of Medicine 84 1063-1066. (doi:10.1016/0002-9343(88)90312-9)
15. Fassnacht M & Allolio B 2009 Clinical management of adrenocortical carcinoma. Best Practice & Research. Clinical Endocrinology & Metabolism 23 273-289. (doi:10.1016/j.beem.2008.10.008)
16. Hofland LJ, van Koetsveld PM & Lamberts SW 1990 Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995. European Journal of Cancer 26 37-44. (doi:10.1016/0277- 5379(90)90254-Q)
17. Johansson MK, Sanderson JT & Lund BO 2002 Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicology in Vitro 16 113-121. (doi:10.1016/S0887-2333(01)00111-4)
18. Kelly DF 2007 Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's syndrome. Neurosurgical Focus 23 E5. (doi:10.3171/foc.2007. 23.3.7)
19. van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ et al. 2006 Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. Journal of Clinical Endocrinology and Metabolism 91 4537-4543. (doi:10.1210/jc.2006-0620)
20. Lamberts SW, Bons EG, Bruining HA & de Jong FH 1987 Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. Journal of Pharmacology and Experimental Therapeutics 240 259-264.
21. Loli P, Berselli ME & TagliaferriM1986 Use of ketoconazole in the treatment of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 63 1365-1371. (doi:10.1210/jcem-63-6-1365)
22. Magill SS, Puthanakit T, Swoboda SM, Carson KA, Salvatori R, Lipsett PA & Hendrix CW 2004 Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients. Antimicrobial Agents and Chemotherapy 48 2471-2476. (doi:10.1128/AAC.48.7.2471-2476.2004)
23. Marchetti O, Majcherczyk PA, Glauser MP, Bille J, Moreillon P & Sanglard D 2001 Sensitive bioassay for determination of fluconazole concentrations in plasma using a Candida albicans mutant hypersusceptible to azoles. Antimicrobial Agents and Chemotherapy 45 696-700. (doi:10.1128/AAC.45. 3.696-700.2001)
24. McCance DR, Hadden DR, Kennedy L, Sheridan B & Atkinson AB 1987 Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clinical Endocrinology 27 593-599. (doi:10.1111/j. 1365-2265.1987.tb01189.x)
25. Michaelis G, Zeiler D, Biscoping J, Fussle R & Hempelmann G 1993 Function of the adrenal cortex during therapy with fluconazole in intensive care patients. Mycoses 36 117-123. (doi:10.1111/j.1439-0507.1993. tb00698.x)
26. Newell-Price J, Bertagna X, Grossman AB & Nieman LK 2006 Cushing's syndrome. Lancet 367 1605-1617. (doi:10.1016/S0140-6736(06)68699-6)
27. Nieman LK 2002 Medical therapy of Cushing's disease. Pituitary 5 77-82. (doi:10.1023/A:1022308429992)
28. Ohlsson A, Cedergreen N, Oskarsson A & Ulleras E 2010 Mixture effects of imidazole fungicides on cortisol and aldosterone secretion in human adrenocortical H295R cells. Toxicology 275 21-28. (doi:10.1016/j.tox. 2010.05.013)
29. van der Pas R, de Herder WW, Hofland L & Feelders RA 2012 New developments in medical therapy of Cushing's syndrome. Endocrine-Related Cancer 13 171-179. (doi:10.1530/ERC-12-0191)
30. Patalano A, Brancato V & Mantero F 2009 Adrenocortical cancer treatment. Hormone Research 71 (Suppl 1) 99-104. (doi:10.1159/000178049)
31. Riedl M, Maier C, Zettinig G, Nowotny P, Schima W& Luger A 2006 Long term control of hypercortisolism with fluconazole: case report and in vitro studies. European Journal of Endocrinology 154 519-524. (doi:10.1530/eje.1. 02120)
32. Santen RJ, Van den Bossche H, Symoens J, Brugmans J & DeCoster R 1983 Site of action of low dose ketoconazole on androgen biosynthesis in men. Journal of Clinical Endocrinology and Metabolism 57 732-736. (doi:10.1210/ jcem-57-4-732)
33. Santhana Krishnan SG & Cobbs RK 2006 Reversible acute adrenal insufficiency caused by fluconazole in a critically ill patient. Postgraduate Medical Journal 82 e23. (doi:10.1136/pgmj.2006.047258)
34. Schteingart DE 2009 Drugs in the medical treatment of Cushing's syndrome. Expert Opinion on Emerging Drugs 14 661-671. (doi:10.1517/ 14728210903413522)
35. Shibata S, Kami M, Kanda Y, Machida U, Iwata H, Kishi Y, Takeshita A, Miyakoshi S, Ueyama J, Morinaga S et al. 2001 Acute adrenal failure associated with fluconazole after administration of high-dose cyclophosphamide. American Journal of Hematology 66 303-305. (doi:10.1002/ ajh.1063)
36. Sonino N 1987 The use of ketoconazole as an inhibitor of steroid production. New England Journal of Medicine 317 812-818. (doi:10.1056/ NEJM198709243171307)
37. Sonino N, Boscaro M, Paoletta A, Mantero F & Ziliotto D 1991 Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clinical Endocrinology 35 347-352. (doi:10.1111/j.1365-2265.1991. tb03547.x)
38. Terrell CL 1999 Antifungal agents. Part II. The azoles. Mayo Clinic Proceedings 74 78-100. (doi:10.4065/74.1.78)
39. Van Allen EM & Ryan CJ 2009 Novel secondary hormonal therapy in advanced prostate cancer: an update. Current Opinion in Urology 19 315-321. (doi:10.1097/MOU.0b013e328329b73a)
40. Veytsman I, Nieman L & Fojo T 2009 Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. Journal of Clinical Oncology 27 4619-4629. (doi:10.1200/JCO.2008.17.2775)
41. Vignati F & Loli P 1996 Additive effect of ketoconazole and octreotide in the treatment of severe adrenocorticotropin-dependent hypercortisolism. Journal of Clinical Endocrinology and Metabolism 81 2885-2890. (doi:10.1210/ jc.81.8.2885)
42. Wang T, Rowland JG, Parmar J, Nesterova M, Seki T & Rainey WE 2012 Comparison of aldosterone production among human adrenocortical cell lines. Hormone and Metabolic Research 44 245-250. (doi:10.1055/s-0031- 1298019)